Citations

Clear

4847 citation(s) found for "Yu, Eric".

Incidence of hematologic malignancy and cause‐specific mortality in the Women's Health Initiative randomized controlled trial of calcium and vitamin D supplementation
Ammann, Eric M. , Haraldsson, Bjarni , Wallace, Robert B. , Johnson, Karen , Lin, Emily M., Link, Brian K. , Drake, Matthew T. , Haraldsson, Bjarni , Desai, Pinkal , Link, Brian K

Mayo Clinic

Cancer | June 27, 2017 | Volume: 123 | Issue: 21 | Pages: 4168-4177

10.1002/cncr.30858 | PMID 28654155 Get It

BACKGROUNDPrior evidence of a possible link between vitamin D status and hematologic malignancy (HM) in humans comes from observational studies, leaving unresolved the question of whether a true causal relationship exists.METHODSThe authors performed a secondary analysis of data from the Women's Health Initiative Calcium/Vitamin D (CaD) trial, a large randomized controlled trial of CaD supplementation compared with placebo in older women. Kaplan‐Meier and Cox proportional hazards survival analysis methods were used to evaluate the relationship between treatment assignment and 1) incident HM and 2) HM‐specific mortality over 10 years following randomization. HMs were classified by cell type (lymphoid, myeloid, or plasma cell) and analyzed as distinct endpoints in secondary analyses.RESULTSA total of 34,763 Women's Health Initiative CaD trial participants (median age, 63 years) had complete baseline covariate data and were eligible for analysis. Women assigned to CaD supplementation had a significantly lower risk of incident HM (hazard ratio [HR], 0.80; 95% confidence interval [95% CI], 0.65‐0.99) but not HM‐specific mortality (HR, 0.77 [95% CI, 0.53‐1.11] for the entire cohort; and HR, 1.03 [95% CI, 0.70‐1.51] among incident HM cases after diagnosis). In secondary analyses, protective associations were found to be most robust for lymphoid malignancies, with HRs of 0.77 (95% CI, 0.59‐1.01) and 0.46 (95% CI, 0.24‐0.89), respectively, for cancer incidence and mortality in those assigned to CaD supplementation.CONCLUSIONSThe current post hoc analysis of data from a large and well‐executed randomized controlled trial demonstrates a protective association between modest CaD supplementation and HM risk in older women. Additional research concerning the relationship between vitamin D and HM is warranted. Cancer 2017;123:4168–4177. © 2017 American Cancer Society.
Gadolinium Deposition in Human Brain Tissues after Contrast-enhanced MR Imaging in Adult Patients without Intracranial Abnormalities
McDonald, Robert J. , Kallmes, David F. , Jentoft, Mark E. , Paolini, Michael A., Murray, David , Williamson, Eric E. , Eckel, Laurence J. , Murray, David L., McDonald, Jennifer S.

Mayo Clinic

Radiology | June 27, 2017 | Volume: 285 | Issue: 2 | Pages: 546-554

10.1148/radiol.2017161595 | PMID 28653860 Get It

Erratum to: Development of a Unifying Target and Consensus Indicators for Global Surgical Systems Strengthening: Proposed by the Global Alliance for Surgery, Obstetric, Trauma, and Anaesthesia Care (The G4 Alliance)
Haider, Adil H. , Scott, John W. , Gause, Colin D., Meheš, Mira, Hsiung, Grace, Prelvukaj, Albulena, Yanocha, Dana, Baumann, Lauren M., Ahmed, Faheem , Ahmed, Naeem , Anderson, Sara, Angaté, Hervé, Arfaa, Lisa, Asbun, Horacio J. , Ashengo, Tigistu Adamu , Asuman, Kisembo, Bickler, Stephen W. , Billingsley, Saul, Bird, Peter, Botman, Matthijs , Butler, Marilyn, Buyske, Jo, Capozzi, Angelo, Casey, Kathleen , Clayton, Charles, Cobey, James C., Cotton, Michael , Deckelbaum, Dan, Derbew, Miliard , deVries, Catherine R. , Dillner, Jeanne, Downham, Max, Draisin, Natalie, Echinard, David, Elneil, Sohier , ElSayed, Ahmed , Estelle, Abigail, Finley, G. Allen , Frenkel, Erica, Frykman, Philip K., Gheorghe, Florin, Gore‐Booth, Julian, Henker, Richard , Henry, Jaymie , Henry, Orion, Hoemeke, Laura , Ibanga, Iko, Jackson, Eric V., Jani, Pankaj , Johnson, Walter D. , Jones, Andrew , Kassem, Zeina, Kocan, Abbey, Krishnaswami, Sanjay , Lane, Robert H. , Latif, Asad , Levy, Barbara , Linos, Dimitrios , Linz, Peter E., Listwa, Louis A., Magee, Declan, Makasa, Emmanuel , Marin, Michael L. , Martin, Claude , McQueen, Kelly, Morgan, Jamie , Moser, Richard , Neighbor, Robert, Novick, William M. , Ogendo, Stephen, Omigbodun, Akinyinka , Onajin‐Obembe, Bisola , Parsan, Neil, Philip, Beverly K., Price, Raymond R. , Rasheed, Shahnawaz, Ratel, M, Reynolds, Cheri, Roser, Steven M. , Rowles, Jackie , Samad, Lubna , Sampson, John , Sanghvi, Harshadkumar, Sellers, Marchelle L., Sigalet, David L. , Steffes, Bruce C., Stieber, Erin, Swaroop, Mamta , Tarpley, John L. , Varghese, Asha , Varughese, Julie, Wagner, Richard, Warf, Benjamin C. , Wetzig, Neil , Williamson, Susan , Wood, Joshua, Zeidan, Anne, Zirkle, Lewis G. , Allen, Brendan, Abdullah, Fizan , Asbun, Horacio, Ayala, Ruben , Butler, Marilyn, Gheorghe, Florin, Hoffman, David C. , Lane, Robert, Varughese, Julie

Mayo Clinic

World Journal of Surgery | June 22, 2017 | Volume: 41 | Issue: 10 | Pages: 2423-2425

10.1007/s00268-017-4067-7 | PMID 28642965 Get It

PRELIMINARY RESULTS FROM AN OPEN‐LABEL, PHASE II STUDY OF TIPIFARNIB IN RELAPSED OR REFRACTORY PERIPHERAL T‐CELL LYMPHOMA
Sokol, Lubomir , Jacobsen, Eric D. , Burrows, Francis , Melvin, C., Mishra, Vishnu S. , Scholz, Catherine, Witzig, Thomas E. , Sokol, Lubomir , Advani, Ranjana H. , Mondejar, Rufino , Piris, Miguel Á. , Gualberto, Antonio

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 251-252

10.1002/hon.2438_115 Get It

THE 23‐GENE GENE EXPRESSION‐BASED ASSAY DOES NOT PREDICT INTERIM PET SCAN RESULTS AFTER ABVD IN ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA IN THE US INTERGROUP S0816 TRIAL
Li, H., Harvey, Yasmin , Chan, Fong Chun , Boyle, M., Straus, David J. , Sweetenham, John , Fanale, Michelle A. , Cook, James R. , Leonard, John P. , Friedberg, Jonathan W. , Gascoyne, Randy D. , Scott, David W. , Mottok, Anja , Evens, Andrew M. , Schöder, Heiko , Bartlett, Nancy L. , Barr, Paul M. , Hsi, Eric D. , Kahl, Brad S. , LeBlanc, Michael , Steidl, Christian , Rimsza, Lisa M. , Press, Oliver W.

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 92-93

10.1002/hon.2437_81 Get It

Increasing Body Mass Index Is Associated with Worse Outcomes After Shoulder Arthroplasty
Wagner, Eric R. , Schleck, Cathy D. , Harmsen, William S. , Cofield, Robert H. , Sperling, John W. , Elhassan, Bassem T. , Houdek, Matthew T. , Sánchez‐Sotelo, Joaquín , Wagner, Eric R

Mayo Clinic

Journal of Bone and Joint Surgery | June 7, 2017 | Volume: 99 | Issue: 11 | Pages: 929-937

10.2106/jbjs.15.00255 | PMID 28590378 Get It

Background: Although obesity is associated with increased complication rates after lower-extremity arthroplasty, there is a relative paucity of studies examining the effect of body mass index (BMI) on shoulder arthroplasty. The purpose of this investigation was to evaluate the effect of BMI on implant survival and the rate of complications after shoulder arthroplasty. Methods: Using an institutional total joint registry, 4,567 consecutive shoulder arthroplasty cases from 1970 to 2013 were studied. The mean BMI was 29.7 kg/m 2 (range, 14 to 66 kg/m 2 ), with 1,622 patients (36%) with a BMI of 30 to 40 kg/m 2 and 297 patients (7%) with a BMI of >40 kg/m 2 . There were 2,493 female patients (55%). BMI was dichotomized after examination of the smoothing spline curve. The associations of factors and complications were assessed using Cox proportional hazard regression analysis. Results: Increasing BMI was associated with an increased risk of a revision surgical procedure, reoperation, revision for mechanical failure, and superficial infection, and it was negatively associated with risk of a periprosthetic fracture. The risk of a revision surgical procedure increased in a linear fashion with increasing BMI (hazard ratio [HR], 1.05, or a 5% increased risk per 1 unit of BMI; p = 0.03). Increased BMI was also associated with an increased risk of revision for mechanical failure (HR, 1.05; p = 0.004). In a multivariate model, the association of BMI and risk of a revision for any reason, revision for mechanical failure, and reoperation maintained significance (p ≤ 0.02). The most marked association between increasing BMI and any complication in shoulder arthroplasty was its association with superficial wound infection (HR, 1.09; p = 0.03). Conclusions: Increasing BMI is strongly associated with increased rates of revision surgical procedures and postoperative complications after shoulder arthroplasty. It is important to consider these findings when counseling patients, estimating risks, and estimating complication risks in policy decisions. Level of Evidence: Prognostic Level IV . See Instructions for Authors for a complete description of levels of evidence.
Phenoconversion from probable rapid eye movement sleep behavior disorder to mild cognitive impairment to dementia in a population‐based sample
Jung, Youngsin, Boot, Brendon , Mielke, Michelle M. , Ferman, Tanis J. , Geda, Yonas E. , Christianson, Teresa J., Louis, Erik K. St. , Silber, Michael H. , Petersen, Ronald C. , Christianson, Teresa J H, St Louis, Erik K, McDade, Eric , Knopman, David S. , Boeve, Bradley F. , St Louis, E K , Mielke, Michelle M , Geda, Yonas E , Ferman, Tanis J

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | May 31, 2017 | Volume: 8 | Issue: 1 | Pages: 127-130

10.1016/j.dadm.2017.05.004 | PMID 28649596 Get It

AbstractIntroductionRapid eye movement sleep behavior disorder (RBD) is strongly associated with synucleinopathies. In 2012, we reported an increased risk of mild cognitive impairment (MCI) and Parkinson disease (PD) in cognitively normal Olmsted County, Minnesota, residents, aged 70 to 89 years with probable RBD. Here, we examine their progression to dementia and other neurodegenerative phenotypes.MethodsFifteen participants with RBD who were diagnosed with either MCI or PD were longitudinally followed, and their subsequent clinical courses were reviewed.ResultsOver 6.4 ± 2.9 years, six of the 14 participants with MCI developed additional neurodegenerative signs, five of whom had Lewy body disease features. Four of them progressed to dementia at a mean age 84.8 ± 4.9 years, three of whom met the criteria for probable dementia with Lewy bodies. One subject with PD developed MCI, but not dementia.DiscussionOur findings from the population‐based sample of Olmsted County, Minnesota, residents suggest that a substantial number of RBD patients tend to develop overt synucleinopathy features over time, and RBD patients who develop MCI and subsequent dementia have clinical features most consistent with dementia with Lewy bodies.
Beta-2 Adrenergic Receptor Genotype Influences Power Output in Healthy Subjects
Kelley, Eli F. , Johnson, Bruce D., Snyder, Eric M.

Mayo Clinic

Journal of Strength and Conditioning Research | May 27, 2017 | Volume: 31 | Issue: 8 | Pages: 2053-2059

10.1519/jsc.0000000000001978 | PMID 28557859 Get It

Abstract Kelley, EF, Johnson, BD, and Snyder, EM. Beta-2 adrenergic receptor genotype influences power output in healthy subjects. J Strength Cond Res 31(8): 2053–2059, 2017—The purpose of this study was to determine the effects of ADRB2 genotypes on muscle function (absolute power and relative power) in healthy subjects. We performed genotyping of the ADRB2 (amino acid 16) and high-intensity, steady-state exercise on 77 healthy subjects (AA = 18, AG = 25, GG = 34). There were no differences between genotype groups in age, height, weight, or body mass index (BMI) (age = 28.9 ± 5.7 years, 27.9 ± 5.7 years, 29.2 ± 5.9 years, height = 170.7 ± 8.6 cm, 174.9 ± 8.7 cm, 173.4 ± 9.6 cm, weight = 68.5 ± 13.0 kg, 75.0 ± 12.9 kg, 74.4 ± 12.9 kg, and BMI = 23.4 ± 3.9, 24.4 ± 2.9, 24.7 ± 3.4, for AA, AG, and GG, respectively). The genotype groups differed significantly in watts, and watts/V̇ o 2 with heavy exercise (watts = 186.3 ± 54.6, 237.8 ± 54.4, 219.4 ± 79.5, watts/V̇ o 2 = 0.08 ± 0.006, 0.09 ± 0.005, 0.08 ± 0.006). There was a trend toward significance ( p = 0.058) for W·kg −1 (2.7 ± 0.4, 3.2 ± 0.5, 2.9 ± 0.8, for AA, AG, and GG, respectively). These data suggest that genetic variation of the ADRB2 may influence relative strength in healthy subjects and may become an important genetic determinant of muscular strength and functional capacity in patients with diseases that result in a loss of muscle strength.
Sex differences in fitness and cardiac function during exercise in adolescents with chronic fatigue
Pianosi, Paolo T. , Emerling, Eric, Mara, Kristin C. , Weaver, Amy L. , Pianosi, P T , Fischer, Philip R. , Mara, Kristin C

Mayo Clinic

Scandinavian Journal of Medicine & Science in Sports | May 25, 2017 | Volume: 28 | Issue: 2 | Pages: 524-531

10.1111/sms.12922 | PMID 28543923 Get It

Females demonstrate less robust Frank‐Starling mechanism with respect to cardiac preload than males at rest. We asked whether this phenomenon would also affect cardiac performance during exercise. We hypothesized that stroke volume (SV) response to exercise would be more limited in deconditioned females such that cardiac output would be mainly rate dependent, compared with males. We conducted a chart audit of clinical exercise tests performed by adolescents with chronic fatigue. Oxygen uptake () was measured breath‐by‐breath at rest and during cycle ergometry, while cardiac output was measured by acetylene rebreathing at rest plus 2‐3 subthreshold workloads. SV response was analyzed in two ways: after normalization for body surface area (SV index, SVI) and as percentage change from resting values. Among 304 adolescents (78% females) with chronic fatigue, 189 (80%) of 236 females and 52 (76%) of 68 males were deconditioned (peakO2 <90% predicted). Heart rate trajectory during exercise was steeper for unfit than fit females, 70 vs 61 beat·min−1 per L·min−1 , (P=.003); but not for males, 47 vs 42 beat·min−1 per L·min−1 (P=.23). The highest measured SVI did not differ between unfit vs fit females (42.8 vs 41.5 mL·m−2, P=.39) while fit males showed larger SV during exercise than their unfit peers (highest SVI 55.9 vs 48.0 mL·m−2, P=.014). Both qualitative and quantitative sex differences exist in SV responses to exercise among chronically fatigued adolescents, suggesting volume loading may be more efficacious in girls.
Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation
Black‐Maier, Eric , Kim, Sunghee , Steinberg, Benjamin A. , Fonarow, Gregg C. , Kowey, Peter R. , Ansell, Jack , Mahaffey, Kenneth W. , Go, Alan S. , Piccini, Jonathan P. , Investigators, for the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF), Freeman, James V. , Gersh, Bernard J. , Naccarelli, Gerald V. , Hylek, Elaine M. , Peterson, Eric D. , Investigators, for the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF), Steinberg, Benjamin A

Mayo Clinic

Clinical Cardiology | May 23, 2017 | Volume: 40 | Issue: 9 | Pages: 746-751

10.1002/clc.22726 | PMID 28543401 Get It

BackgroundOral anticoagulation (OAC) therapy is associated with increased periprocedural risks after cardiac implantable electronic device (CIED) implantation. Patterns of anticoagulation management involving non–vitamin K antagonist oral anticoagulants (NOACs) have not been characterized.HypothesisAnticoagulation strategies and outcomes differ by anticoagulant type in patients undergoing CIED implantation.MethodsUsing the nationwide Outcomes Registry for Better Informed Treatment of Atrial Fibrillation, we assessed how atrial fibrillation (AF) patients undergoing CIED implantation were cared for and their subsequent outcomes. Outcomes were compared by oral anticoagulant therapy (none, warfarin, or NOAC) as well as by anticoagulation interruption status.ResultsAmong 9129 AF patients, 416 (5%) underwent CIED implantation during a median follow‐up of 30 months (interquartile range, 24–36). Of these, 60 (14%) had implantation on a NOAC. Relative to warfarin therapy, those on a NOAC were younger (70.5 years [range, 65–77.5 years] vs 77 years [range, 70–82 years]), had less valvular heart disease (15.0% vs 31.3%), higher creatinine clearance (67.3 [range, 59.7–99.0] vs 65.8 [range, 50.0–91.6]), were more likely to have persistent AF (26.7% vs 22.9%), and use concomitant aspirin (51.7% vs 35.2%). OAC therapy was commonly interrupted for CIED in 64% (n = 183 of 284) of warfarin patients and 65% (n = 39 of 60) of NOAC patients. Many interrupted patients received intravenous bridging anticoagulation: 33/183 (18%) interrupted warfarin and 4/39 (10%) interrupted NOAC patients. Thirty‐day periprocedure bleeding and stroke adverse events were infrequent.ConclusionsManagement of anticoagulation among AF patients undergoing CIED implantation is highly variable, with OAC being interrupted in more than half of both warfarin‐ and NOAC‐treated patients. Bleeding and stroke events were infrequent in both warfarin and NOAC‐treated patients.